SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. (2395.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	32.5B	32.5B	32.4B	26.4B	25.1B
Cost of Revenue	3.4B	16.3B	15.5B	12.2B	12.0B
Gross Profit	3.1B	16.2B	17.0B	14.3B	13.0B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	3.4B	13.6B	14.0B	10.1B	7.8B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	3.4B	13.6B	14.0B	10.1B	7.8B
Cost and Expenses	29.9B	29.9B	29.4B	22.3B	19.8B
Operating Income (EBIT)	2.7B	2.7B	3.0B	4.2B	5.2B
Non-Operating
Interest Income	6.7M	237.8M	97.2M	186.6M	57.4M
Interest Expense	57.8M	293.2M	202.7M	138.8M	125.1M
Net Interest Income	(51.2M)	(55.4M)	(105.5M)	47.8M	(67.7M)
Other Non-Op Income/Expense	856.7M	3.2B	3.5B	2.9B	3.9B
Non-Operating Income (excl Interest)	908.6M	3.2B	3.7B	3.1B	4.2B
EBT (Pre-Tax Income)	333.5M	6.2B	6.0B	7.0B	7.8B
Income Tax Expense	77.0M	1.7B	1.1B	1.5B	1.7B
Bottom Line
Net Income	4.6B	4.6B	4.9B	5.5B	6.1B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	4.6B	4.6B	4.9B	5.5B	6.1B
Per Share
Basic EPS	¥110	¥110	¥118	¥133	¥146
Diluted EPS	¥110	¥110	—	—	—
Revenue Per Share	¥781	¥781	¥779	¥635	¥603
Shares
Basic Shares Outstanding	41.6M	41.6M	41.6M	41.6M	41.6M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	6.0B	5.5B	5.9B	6.8B
D&A	—	3.3B	2.5B	1.8B	1.5B
EBIT	2.7B	2.7B	3.0B	4.2B	5.2B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026